Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.010
-0.010 (-0.33%)
Nov 20, 2024, 4:00 PM EST - Market closed
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $354.62K in the quarter ending September 30, 2024, with 11.00% growth. This brings the company's revenue in the last twelve months to $1.31M, up 130.31% year-over-year. In the year 2023, Aprea Therapeutics had annual revenue of $583.23K.
Revenue (ttm)
$1.31M
Revenue Growth
+130.31%
P/S Ratio
11.38
Revenue / Employee
$187,263
Employees
7
Market Cap
16.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 583.23K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPRE News
- 4 weeks ago - Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - GlobeNewsWire
- 6 weeks ago - Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - GlobeNewsWire
- 2 months ago - UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - GlobeNewsWire